CoSyne Therapeutics is a precision medicine biotech focused on brain cancer, combining patient-derived tumour models, single-cell perturbation data, and advanced AI to accelerate drug discovery. Its “polymathic AI” platform integrates biology and chemistry foundation models to identify precision drug targets, companion biomarkers, and combination therapies for underserved brain diseases. By vertically unifying data generation, computational modelling, and translational biology, CoSyne aims to deliver faster, more targeted treatments for patients with glioblastoma and other high-need neurological cancers.
